These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 6453246)

  • 1. [Clinical evaluations of antithrombin III and alpha 2-plasmin inhibitor assay method with chromogenic substrates (S-2238, S-2251 (author's transl)].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1981 Feb; 29(2):179-82. PubMed ID: 6453246
    [No Abstract]   [Full Text] [Related]  

  • 2. [Evaluation of two-stage antithrombin III assay using new chromogenic peptide substrates (author's transl)].
    Asai K; Takagi A; Otsubo M
    Rinsho Byori; 1980 Jan; 28(1):76-80. PubMed ID: 7373879
    [No Abstract]   [Full Text] [Related]  

  • 3. [Assay of antithrombin III activity using chromogenic substrate (author's transl)].
    Koresawa S; Matsuda N; Ueda S
    Rinsho Byori; 1982 Jan; 30(1):54-8. PubMed ID: 7087231
    [No Abstract]   [Full Text] [Related]  

  • 4. [Diagnosis of increased thrombotic tendency with chromogenic substrates].
    Vinazzer H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):135-41. PubMed ID: 6177594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The determination of inhibitors of haemostasis using chromogenic substances (author's transl)].
    Jürgens H; von Voss H; Göbel U
    Klin Padiatr; 1980 Jul; 192(4):330-5. PubMed ID: 7192767
    [TBL] [Abstract][Full Text] [Related]  

  • 6. False low antithrombin III results in renal disease.
    Fisher AH
    Med Lab Sci; 1985 Jan; 42(1):44-7. PubMed ID: 3982246
    [No Abstract]   [Full Text] [Related]  

  • 7. [On the determination of plasma antithrombin III with chromogenic peptide substrate (author's transl)].
    Nakamura S; Takizawa N; Nakanishi K; Igarashi M
    Rinsho Byori; 1980 Jan; 28(1):81-6. PubMed ID: 7373880
    [No Abstract]   [Full Text] [Related]  

  • 8. Improved assay conditions for automated antithrombin III determinations with the chromogenic substrate S-2238.
    van Voorthuizen H; Kluft C
    Thromb Haemost; 1984 Dec; 52(3):350-3. PubMed ID: 6531759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Changes of antithrombin III, alpha2-macroglobulin, alpha1-antitrypsin, C1-inhibitor and alpha2-plasmin inhibitor in arteriosclerotic diseases and diabetes mellitus (author's transl)].
    Matsuda T
    Rinsho Ketsueki; 1978 Jul; 19(7):947-54. PubMed ID: 81330
    [No Abstract]   [Full Text] [Related]  

  • 10. [The changes of alpha 2-plasmin inhibitor, and notably urokinase activities in blood measured by synthetic chromogenic substrates S-2444 after urokinase administration].
    Itoh Y; Tsuji K; Tanaka N; Yamada M; Nakanishi M; Ishihara M; Kobayashi M
    Nihon Sanka Fujinka Gakkai Zasshi; 1983 Jan; 35(1):68-76. PubMed ID: 6338134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modification of the immediate plasmin inhibition assay to secure linearity of the reference curve with the chromogenic substrate S-2251.
    Jespersen J; Gram J; Sidelmann J
    Thromb Haemost; 1984 Apr; 51(2):298. PubMed ID: 6740562
    [No Abstract]   [Full Text] [Related]  

  • 12. Methodological considerations on antithrombin determination.
    Abildgaard U
    Acta Chir Scand Suppl; 1982; 509():97-9. PubMed ID: 6962626
    [No Abstract]   [Full Text] [Related]  

  • 13. [Studies on tissue thromboplastic activity assay method with chromogenic substrates (S-2222)].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1984 Mar; 32(3):313-6. PubMed ID: 6737742
    [No Abstract]   [Full Text] [Related]  

  • 14. [Use of chromogenic substrates for the diagnosis of blood coagulation and fibrinolytic disorders].
    Bokarev IN; Butorov VN; Loginov LE
    Ter Arkh; 1981; 53(2):118-24. PubMed ID: 6452714
    [No Abstract]   [Full Text] [Related]  

  • 15. [Studies on plasma prekallikrein assay method with chromogenic substrates (S-2302)].
    Fukuda C; Iijima K; Nakamura K
    Rinsho Byori; 1983 Feb; 31(2):219-22. PubMed ID: 6190027
    [No Abstract]   [Full Text] [Related]  

  • 16. [Studies of antithrombin III assay using new chromogenic peptide substrates (author's transl)].
    Asai K; Takagi A; Inagaki Y; Setsuda Y
    Rinsho Byori; 1979 Dec; 27(12):1121-5. PubMed ID: 541858
    [No Abstract]   [Full Text] [Related]  

  • 17. [Comparison of colorimetric, fluorometric and spectrophotometric methods for measuring antithrombin III using synthetic substrates].
    Uete T
    Rinsho Byori; 1984 Nov; 32(11):1258-62. PubMed ID: 6520982
    [No Abstract]   [Full Text] [Related]  

  • 18. [Clinical evaluation of prothrombin assay using chromogenic peptide substrates (author's transl)].
    Akiyama Y; Hibiya Y; Nakatake T; Kazama M
    Rinsho Byori; 1980 Nov; 28(11):1131-5. PubMed ID: 7241816
    [No Abstract]   [Full Text] [Related]  

  • 19. [Significance of the amidolytic method in the typing of congenital antithrombin III deficiency].
    Losonczy H; Nagy I
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1982; 109(1):184-8. PubMed ID: 6177603
    [No Abstract]   [Full Text] [Related]  

  • 20. [Automation of colorimetry using chromogenic substrates, with special reference to blood coagulation disorders in acute myelocytic leukemia].
    Hashizume K; Tanaki T; Horita H; Yoshitani H; Kumatani Y; Matsuda T; Ito K
    Rinsho Byori; 1985 Feb; Spec No 61():114-8. PubMed ID: 3858561
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.